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The development of wild-type, unmodified Type 3 Dearing strain reovirus as an anticancer
agent has currently expanded to 32 clinical trials (both completed and ongoing) involving
reovirus in the treatment of cancer. It has been more than 30 years since the potential
of reovirus as an anticancer agent was first identified in studies that demonstrated the
preferential replication of reovirus in transformed cell lines but not in normal cells. Later
investigations have revealed the involvement of activated Ras signaling pathways (both
upstream and downstream) and key steps of the reovirus infectious cycle in promoting
preferential replication in cancer cells with reovirus-induced cancer cell death occurring
through necrotic, apoptotic, and autophagic pathways. There is increasing evidence that
reovirus-induced antitumor immunity involving both innate and adaptive responses also
contributes to therapeutic efficacy though this discussion is beyond the scope of this arti-
cle. Here, we review our current understanding of the mechanism of oncolysis contributing
to the broad anticancer activity of reovirus. Further understanding of reovirus oncolysis is
critical in enhancing the clinical development and efficacy of reovirus.
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INTRODUCTION
REOVIRUS STRUCTURE
Reovirus is a member of the Reoviridae family of viruses whose
name was coined in 1959 and derived from the fact that it is
commonly isolated from the respiratory and enteric tract with-
out an association with clinical symptoms, or an orphan virus,
although infection can be associated with mild respiratory and
enteric symptoms in humans (1–5). Antibody neutralization and
hemagglutination-inhibition studies have identified three distinct
serotypes of reovirus [Type 1 Lang, Type 2 Jones, Type 3 Abney,
and Type 3 Dearing (T3D)] (1, 3, 5).
Reovirus is a non-enveloped double-stranded RNA (dsRNA)
virus comprised of an outer and inner protein shell which alto-
gether form a 20-sided icosahedral capsid (1, 2, 4, 6). The entire
virus has an approximate diameter of 80 nm and houses its genome
consisting of 10 segments of dsRNA that encode for structural and
non-structural proteins involved in viral attachment, viral repli-
cation, virulence, and formation of viral inclusions (Figure 1) (1,
4, 7–10).
REOVIRUS INFECTIOUS CYCLE
The infectious life cycle of reovirus begins with attachment of
viral protein sigma 1 (σ1) to target cell surface sialic acid residues,
which have been shown to be α-linked 5-N -acetylneuraminic
acid (Neu5Ac) and ganglioside GM2 glycan for serotypes T3D
and Type 1 Lang, respectively (8, 11–13). Attachment to cell sur-
face glycans facilitates binding to junctional adhesion molecule-A
(JAM-A) which, in turn, results in internalization of reovirus via
receptor beta 1 (β-1)-integrin mediated endocytosis (14, 15). Once
internalized, the virus is transported to early and late endosomes
where it undergoes proteolytic disassembly and degradation of the
outer shell proteins sigma 3 (σ3) and mu 1 (µ1), in particular, by
cysteine cathepsin proteases resulting in the formation of infec-
tious subvirion particles (ISVPs) and ultimately in the release of
transcriptionally active viral core particles, mediated by cleavage
fragments of viral capsid proteins, into the cytoplasm (16–20).
Of note, functional microtubules appear to be required, in part,
for the process of endocytic sorting following internalization (21).
ISVPs may also be formed from proteolysis by extracellular pro-
teases, such as those in the gastrointestinal tract, allowing their
direct entry into cells via membrane penetration (4, 22).
The viral core particles contain the necessary machinery includ-
ing RNA-dependent RNA polymerase, guanylyltransferase, and
methyltransferase to initiate viral replication (1, 2, 4–7). Activated
RNA-dependent RNA polymerase begins primary transcription
within the core particles resulting in the release of primary tran-
scripts that, along with protein products of early translation, form
complexes or inclusions where further transcription and trans-
lation occur which, in turn, ultimately lead to viral replication
and assembly, host cell death, and progeny release (1, 2, 4–7). The
events following virus internalization, endocytic processing, and
viral core release remain poorly understood (Figure 1).
MECHANISM OF ONCOLYSIS
EARLY INVESTIGATIONS
The potential for wild-type reovirus as an anticancer agent was
identified more than 30 years ago when studies demonstrated the
preferential replication of reovirus in transformed cell lines but not
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FIGURE 1 | Reovirus structure and infectious cycle. (A) Reovirus is a
non-enveloped double-stranded RNA (dsRNA) virus approximately 80 nm in
diameter. The viral genome, consisting of 10 segments of dsRNA, is
contained within an outer and inner capsid and encodes for structural
proteins comprising the outer capsid including sigma 1 (σ1), sigma 3 (σ3),
lambda 2 (λ2), and mu 1 (µ1), structural proteins comprising the inner
capsid including sigma 2 (σ2), lambda 1 (λ1), lambda 3 (λ3), and mu 2 (µ2),
and non-structural proteins including sigma 1s (σ1s), sigma NS (σNS), mu
NS (µNS), and mu NSC (µNSC). σ1 has been identified as the viral
attachment protein, µ1, µ2, and λ3 serve roles in viral replication, σ1s and
σ3 appear to have roles in virulence, and σNS, µNS, and µNSC appear to be
involved in the formation of viral inclusions. Figure reproduced with
permission from ViralZone, SIB Swiss Institute of Bioinformatics. (B) Viral
attachment to host cell surface glycans results in internalization of reovirus
via receptor-mediated endocytosis. Alternatively, infectious subvirion
particles (ISVPs) can be formed from proteolysis by extracellular proteases
allowing their direct entry into cells via membrane penetration. Once
internalized, the virus is transported to early and late endosomes where it
undergoes proteolytic disassembly and degradation resulting in the
formation of ISVPs and subsequently in the release of transcriptionally
active viral core particles into the cytoplasm. Activated RNA-dependent RNA
polymerase begins primary transcription within the core particles resulting
in the release of primary transcripts that, along with protein products of
early translation, form complexes or inclusions where further transcription
and translation occur which, in turn, ultimately lead to viral replication and
assembly, host cell death, and progeny release.
in normal cells (23, 24). The mechanism of oncolysis by reovirus
remained largely unknown until murine cell lines transfected with
genes encoding the epidermal growth factor receptor (EGFR)
demonstrated increased susceptibility to reovirus infection (25).
Normally, ligand-binding to EGFR activates the tyrosine kinase
activity of EGFR and results in the autophosphorylation of the
receptor’s cytoplasmic domain leading to the recruitment of
phosphotyrosine-binding adaptor molecules such as Shc and Grb2
(26). Grb2, with or without association with Shc, recruits the gua-
nine nucleotide exchange factor (GEF) son of sevenless (SOS) to
the plasma membrane where it activates the small G protein Ras
by promoting the exchange of GTP for GDP on Ras and therefore
converting it from an inactivated GDP-bound state to an activated
GTP-bound state (Ras-GTP) (26). Ras-GTP can then subsequently
activate numerous downstream signaling pathways involved in cel-
lular differentiation and proliferation (26). An example of one
such pathway, which has been well characterized, involves Ras-
GTP association with Raf-1 that activates the kinase activity of
Raf resulting in the phosphorylation and activation of mitogen-
activated protein kinase (MAPK) called MEK1 and MEK2 (26).
Activated MEKs, in turn, phosphorylate and activate extracellular
signal regulated kinases (ERKs) that ultimately translocate to the
nucleus and partake in a number of pathways involved in cellular
processes including transformation (26).
Interestingly, cell lines naturally resistant to reovirus infection
demonstrated enhanced susceptibility when transformed with the
v-erbB oncogene, which encodes for a truncated form of the EGFR
lacking the extracellular ligand-binding domain but possessing
constitutive tyrosine kinase activity, suggesting that reovirus infec-
tion is facilitated by EGFR-mediated pathways rather than binding
of the virus to EGFR itself (27). Activating Ras mutations have
been associated with approximately 30% of all human cancers
though this number likely underestimates the true prevalence of
activated Ras pathways in cancer given that mutations upstream
and downstream of the Ras signaling pathway have also been
associated with cellular transformation (28, 29). Not surprisingly,
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subsequent studies investigated the facilitation of reovirus infec-
tion by activated downstream EGFR-mediated pathways and, in
particular, the activated Ras signaling pathway to uncover potential
relationships to the mechanism of selective oncolysis.
ACTIVATED Ras SIGNALING PATHWAY
Indeed, the downstream targets or intermediates to such pathways
were elucidated when NIH-3T3 fibroblasts transfected with con-
stitutively activated SOS or Ras oncogenes resulted in enhanced
susceptibility to reovirus infection (30). Importantly, this find-
ing occurred only in the presence of a zinc-inducible promoter,
ZnSO4, which suggested that the activated Ras protein itself, rather
than the effects of prolonged transformation, was sufficient to
confer sensitivity to reovirus infection (30). Ras-GTP, however, is
known to stimulate over more than 18 downstream effectors with
the best characterized being the Raf kinases, the phosphatidyli-
nositol 3-kinase (PI3K), and the GEFs for the small G protein Ral
pathways (RalGEF) (29). Later studies aimed to narrow the list
of potential downstream effectors of Ras important to reovirus
oncolysis (31).
When Ras-transformed NIH-3T3 fibroblasts expressing muta-
tions in the effector-binding domains of the Ras protein were used,
reovirus replication was found to be independent of signaling
through Raf or PI3K downstream pathways (31). Only the V12G37
mutant, which retained RalGEF signaling capability, renderedRas-
transformed cells susceptible to reovirus infection while the use of
a dominant-negative mutant of Ral rendered transformed cells
non-permissive to reovirus infection (31). Interestingly, an acti-
vated mutant of RalGEF, Rlf, permitted reovirus replication in the
absence of an activating Ras mutation (31). Lastly, it was demon-
strated that p38 kinase (a downstream effector of RalGEF), but not
stress-activated c-Jun NH2-terminal protein kinase (JNK), plays a
role in establishing reovirus infection (31). In short, these find-
ings implicate the Ras/RalGEF/p38 pathway in the promotion of
selective reovirus replication (Figure 2) (31).
Early evidence suggested that increased expression of reovirus
proteins was observed in Ras-transformed cells and correlated
with elevated virus titers, while relatively impaired expression
was observed in untransformed cells (29, 30). In untransformed
cells, the inhibition of translation appeared to be a key step in
preventing reovirus replication given that reovirus demonstrated
equivalent binding, entry, and primary transcription in both Ras-
transformed and untransformed cells (30, 31). A separate study
highlighted the potential inhibitory activity of the reovirus struc-
tural protein σ3 on the dsRNA-activated protein kinase (PKR)
(32). As a result, the role of PKR in reovirus oncolysis was
implicated in lieu of the above observations (29).
In the presence of viral infection, viral transcripts are rec-
ognized and bound by receptors including toll-like receptors
(TLRs), retinoic acid-inducible gene I (RIG-I), and melanoma
differentiation-associated protein 5 (MDA5) resulting in the acti-
vation of transcription factors such as nuclear factor kappa light-
chain enhancer of activated B cells (NF-κB) and interferon reg-
ulatory factor 3 (IRF-3) (33, 34). These factors then induce the
release of type I interferons [interferon-beta and -alpha (IFN-β
and -α)] that upregulate the expression of interferon-stimulated
genes (ISGs), including the production of the serine/threonine
kinase, PKR, involved in viral transcript degradation and inhi-
bition of viral protein synthesis (33–35). PKR itself can bind to
dsRNA resulting in dimerization, autophosphorylation, and acti-
vation (35). The same phenomenon has been observed in response
to the presence of reovirus S1 mRNA as well (36). Activated PKR
phosphorylates eukaryotic initiation factor 2α (eIF-2α) rendering
it inactive and thereby leading to the inhibition of protein synthesis
and viral replication (35).
It was determined that PKR remained inactivated in Ras-
transformed cells thereby establishing the link between an acti-
vated Ras signaling pathway and PKR in reovirus oncolysis (30).
The link between Ras-transformed cells and PKR inactivation has
previously been suggested,but the use of a specific inhibitor to PKR
phosphorylation by Strong et al. (30) that restored reovirus trans-
lation in untransformed cells offered evidence to the direct role
PKR plays in determining resistance to selective reovirus replica-
tion (30, 37). Later studies demonstrated thatRas-transformation,
through the MEK/ERK pathway, enhanced reovirus spread in
subsequent rounds of infection by suppressing viral transcript-
induced interferon-beta (IFN-β) production through negative reg-
ulation of RIG-I signaling (33). Accordingly, knockdown of either
RIG-I or PKR led to increased susceptibility of untransformed
cells to reovirus infection (33). The exact mechanism behind the
coordination of Ras-transformation and PKR-mediated promo-
tion of viral replication is unclear, but it remains among the best
characterized processes in the understanding of reovirus oncolysis.
The coordination between the activated Ras signaling path-
way, RIG-I and interferon signaling pathways, and PKR in the
promotion of reovirus translation represents one potential mech-
anism among several emerging concepts detailing the effects of
Ras-transformation on the reovirus infectious cycle (33, 38, 39).
Other steps of the infectious cycle appear to be affected by Ras-
transformation and involved in reovirus oncolysis as well. For
example, in contrast to reovirus infection-susceptible glioma cell
lines andRas-transformed NIH-3T3 fibroblasts, reovirus-resistant
and untransformed cells demonstrated prohibition of viral disas-
sembly or uncoating due to the lack of degradation of σ3 and
cleavage of µ1 proteins indicative of ISVP formation (38). Inter-
estingly, disassembly restrictive cells introduced to ISVPs (in vitro)
or grown as a tumor (in vivo), where elevated levels of active
cathepsin B and L were observed in tumors, demonstrated pro-
ductive reovirus infection and highlighted the significance of
reovirus uncoating to susceptibility to oncolysis (38). Indeed,Ras-
transformation of fibroblastic cell lines is associated with increased
levels of cathepsin proteases (40, 41).
A separate study corroborated these findings when Ras-
transformed NIH-3T3 fibroblasts demonstrated a threefold
enhancement in reovirus uncoating compared to untransformed
cells (39). Importantly, reovirus particles purified from Ras-
transformed cells were four times more infectious than those
from untransformed cells, and progeny release, mediated by
caspase-induced apoptosis, was nine times more efficient in Ras-
transformed cells when compared to untransformed cells (39).
Of note, reovirus-induced apoptosis appears to be regulated, in
part, through JNK signaling though the complexities and host
of mediators involved in apoptosis by reovirus will be discussed
later (42).
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FIGURE 2 | Ras-transformation affects several steps of the reovirus
infectious cycle to promote oncolysis. Ras-transformation affects multiple
steps of the infectious life cycle in promoting reovirus oncolysis by: (1)
enhancing virus uncoating and disassembly, (2) negative regulation of
retinoic acid-inducible gene I (RIG-I) signaling and releasing dsRNA-activated
protein kinase (PKR)-induced translational inhibition, (3) increasing progeny
release through enhanced apoptosis and generating more infectious
progeny, and (4) enhancing viral spread in subsequent rounds of infection.
Reovirus-induced cancer cell death occurs through autophagic, apoptotic,
and necrotic pathways. Programed necrosis or necroptosis occurs through
binding of tumor necrosis factor-α (TNF-α), Fas ligand (Fas), and tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) to death receptors
leading to downstream signaling involving receptor interaction protein
kinase (RIP) 1 and 3, cylindromatosis (CYLD), TNF receptor-associated
factors (TRAFs), stress-activated c-Jun NH2-terminal protein kinase (JNK),
reactive oxygen species (ROS), adenine nucleotide translocase (ANT), poly
ADP-ribose polymerases (PARPs), phospholipases, and lipoxygenases
(LOXs). Apoptosis occurs through both extrinsic [e.g., TRAIL binding to cell
surface death receptor recruits Fas-associated death domain (FADD), which
recruits and activates the initiator caspase-8 that ultimately activates
effector caspases-3 and -7] and intrinsic pathways [cytochrome c and
second mitochondrion-derived activator of caspase (Smac/DIABLO) release
with activation of downstream effector caspases with or without
caspase-9]. Autophagy occurs through endoplasmic reticulum (ER) stress
and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR)-mediated signaling. Dashed arrows represent putative cross-talk
and suggested signaling pathways. EGFR, epidermal growth factor receptor;
SOS, son of sevenless; RalGEF, guanine nucleotide exchange factors (GEFs)
for the small G protein Ral pathways; MEK, mitogen-activated protein kinase
(MAPK) kinase; ERK, extracellular signal regulated kinase; TLRs: toll-like
receptors; MDA5, melanoma differentiation-associated protein 5; IFN-β,
interferon-beta; eIF-2α, eukaryotic initiation factor 2α; NF-κB, nuclear factor
kappa light-chain enhancer of activated B cells; IRF-3, interferon regulatory
factor 3.
Altogether, these studies highlight two important points regard-
ing reovirus oncolysis: (1) although prior studies implicate the
Ras/RalGEF/p38 pathway in the promotion of reovirus oncolysis
independent of Raf and JNK signaling,MEK/ERK,and JNK appear
to have roles in reovirus infectivity and reovirus-induced apopto-
sis, and (2) further understanding of the reovirus infectious cycle
has demonstrated that Ras-transformation affects multiple steps
of the cycle, in addition to viral translation, such as viral uncoat-
ing or disassembly, generation of viral progeny with enhanced
infectivity, release of progeny through enhanced apoptosis, and
viral spread in subsequent rounds of infection (Figure 2) (31, 33,
38–42).
PATHWAYS OF REOVIRUS-INDUCED CELL DEATH
There remains great debate in the pathway(s) by which reovirus
induces cancer cell death. On one hand, intratumoral injections
of reovirus into mouse xenograft models of human head and neck
squamous cell carcinoma (SCC) induced tumor cell death through
overwhelming burden of viral replication or cell lysis as evidenced
by significant necrosis in the absence of apoptosis in pathologic
specimens (43). Indeed, necrotic cell death appears to be a regu-
lated process, more so than once believed, as programed necrosis
or necroptosis is induced by binding of tumor necrosis factor-
α (TNF-α), Fas ligand (FasL), and tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) to death receptors leading to
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downstream signaling involving mediators such as receptor inter-
action protein kinase (RIP) 1 and 3, cylindromatosis (CYLD), TNF
receptor-associated factors (TRAFs), JNK, reactive oxygen species
(ROS), adenine nucleotide translocase (ANT), poly ADP-ribose
polymerases (PARPs), phospholipases, and lipoxygenases (LOXs,
Figure 2) (44–46).
On the other hand, apoptosis is a firmly established means
of reovirus-induced cell death and has been demonstrated
to be caspase-dependent and enhanced by activated Ras sig-
naling (39, 47). Reovirus-induced apoptosis proceeds through
both death receptor-associated (extrinsic) and mitochondrial-
associated (intrinsic) pathways (48). For example, binding of the
ligand TRAIL to the TNF superfamily of cell surface death recep-
tors following reovirus infection recruits the adaptor molecule,
Fas-associated death domain (FADD), which recruits and activates
the initiator caspase-8 that ultimately activates effector caspases-
3 and -7, forming part of the final common pathway for both
extrinsic and intrinsic pathways (Figure 2) (48–50). In addition,
following reovirus infection, the mitochondrial pro-apoptotic
proteins cytochrome c and second mitochondrion-derived acti-
vator of caspase (Smac/DIABLO) are released, without distur-
bance of the mitochondrial membrane potential or release of
apoptosis-inducing factor (AIF), and eventually activate down-
stream effector caspases with or without caspase-9 (caspase-9 is
activated by cytochrome c but has been shown to be dispens-
able in the mitochondrial-associated pathway) (48, 51). There is
a great degree of cross-talk between both apoptotic pathways, for
example, activation of caspase-8 in the extrinsic pathway leads to
the cleavage of the pro-apoptotic protein Bid and results in the
release of cytochrome c and Smac/DIABLO (presumably through
pro-apoptotic proteins Bax or Bak), activation of caspase-9, and
eventual activation of effector caspases (Figure 2) (48, 51).
As previously suggested, viral uncoating or disassembly is crit-
ical for reovirus-induced apoptosis (52). Studies have identified
several key components of the viral structure implicated in apop-
tosis including σ1, sigma 1s (σ1s), and µ1 in association with σ3
(53, 54). Ectopic expression of µ1 activated both extrinsic and
intrinsic apoptotic pathways characterized by activation of initia-
tor caspases-8 and -9, release of cytochrome c and Smac/DIABLO
into the cytosol, and activation of downstream effector caspase-
3 independent of the pro-apoptotic B-cell lymphoma-2 (Bcl-2)
family members Bax and Bak (55).
The complexity of reovirus-induced apoptosis continues to
grow (Figure 2). The roles of TRAIL, Bid, Bax, and Bak in
reovirus-induced apoptosis have previously been discussed (48–
51). As previously mentioned, JNK also regulates reovirus-induced
cell death as activation of caspase-3 and apoptosis were inhib-
ited by cells deficient with MEK kinase 1, an upstream activa-
tor of JNK (42). NF-κB also appears to play crucial roles in
reovirus-induced apoptosis via stabilization of the tumor suppres-
sor p53 and NF-κB-dependent mechanisms leading to Bid cleav-
age (56–58). Apoptosis by reovirus appears to require IRF-3 and
NF-κB, in part, for efficient expression of the pro-apoptotic mem-
ber of the Bcl-2 family, Noxa, independent of IFN-β induction
(34). Reovirus appears to downregulate cellular FLICE inhibitory
protein (cFLIP) and Akt activation to increase susceptibility to
TRAIL-induced apoptosis in ovarian cancer cells and gastric
cancer cells, respectively (59, 60). In neurons, reovirus-induced
apoptosis is facilitated by upregulation of death-associated pro-
tein 6 (Daxx), an adaptor between the Fas death receptor and JNK
signaling cascade, within the cytoplasm (61, 62). Moreover, apop-
tosis appears to be facilitated by reovirus-induced inhibition of
microRNA-let-7d and upregulation of caspase-3 activity (63).
Alternatively, autophagy appears to be yet another mechanism
of reovirus-induced cell death as reovirus infection of multiple
myeloma cells demonstrated oncolysis mediated by both apop-
totic and autophagic pathways (64, 65). Specifically, autophagy,
as detected by Cyto-ID staining and vesicle colocalization with
LC3-II (a marker of autophagosomes), was evident in human
multiple myeloma cells (RPMI 8226) at 24 and 48 h of reovirus
treatment (64). A fourfold reduction in autophagy by 48 h of
reovirus infection was demonstrated when RPMI 8226 cells
were pre-treated with the autophagy inhibitor 3-methyladenine
(3-MA) (64). Understanding of the mechanisms behind mam-
malian reovirus-induced autophagy is limited to the above stud-
ies; however, in vitro studies involving avian reovirus (ARV)
have provided further insight (66, 67). ARV infection of Vero
cells in vitro induced autophagy via PI3K/Akt/mammalian tar-
get of rapamycin (mTOR) signaling detected by immunoblotting
(67). Furthermore, pre-treatment of primary chicken fibroblasts
and Vero cells with rapamycin, an mTOR inhibitor known to
induce autophagy, and chloroquine, an inhibitor of lysosome–
autophagosome fusion and autophagy, resulted in increased and
decreased viral production, respectively, in ARV-infected cells (67).
Separate studies have highlighted that endoplasmic reticulum (ER)
stress not rescuable by the unfolded protein response (UPR) has
been shown to enhance autophagy via negative regulation of the
Akt/tuberous sclerosis protein (TSC)/mTOR pathway (68). Inter-
estingly, reovirus-mediated apoptosis of multiple myeloma cells is
also characterized by the stimulation of ER stress along with induc-
tion of Noxa (69). Indeed, growing evidence suggests autophagy
mediated by PI3K/Akt/mTOR signaling and ER stress as a poten-
tial mechanism of reovirus-induced cancer cell death, although
further investigation is warranted.
Lastly, it should be noted that reovirus-induced cell death in
Ras-transformed cells is not absolute, but rather enhanced or more
efficient relative to untransformed cells (29, 30, 39). The cyto-
pathicity of reovirus infection in normal cells has long been char-
acterized by respiratory and enteric pathogenicity in humans with
seropositivity having been documented in as many as 70–100% of
subjects (1–5). In clinical trials involving reovirus monotherapy
in the treatment of cancer, common treatment-related adverse
effects have included nausea, vomiting, fatigue, fever, myalgias,
and other constitutional symptoms consistent with its relatively
mild and benign viral pathophysiology in humans (1, 2, 4, 6, 7).
The increased sensitivity for replication in cancer cells and excel-
lent toxicity profile demonstrated in recent trials underscore the
promising clinical potential of reovirus as an anticancer agent.
CONCLUSION
Reovirus is a dsRNA virus whose mechanism of oncolysis remains
unclear though activated Ras signaling, involving upstream and
downstream mediators, appears important to permissiveness to
reovirus replication. In promoting oncolysis, Ras-transformation
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affects multiple steps of the infectious life cycle including viral
uncoating and disassembly, releasing PKR-induced translational
inhibition, generation of viral progeny, release of progeny, and
viral spread with reovirus-induced cancer cell death occurring
through necrotic, apoptotic, and autophagic pathways. However,
several studies have highlighted that reovirus oncolysis occurs
independent of activated EGFR and Ras signaling pathways, while
others have linked reovirus oncolysis to cell cycle phase (70–
72). Undoubtedly, despite our progress in understanding reovirus
oncolysis, further investigation into the mechanism of preferen-
tial replication in cancer cells is still warranted to enhance the
antitumor efficacy of reovirus whose development has currently
expanded to 32 clinical trials (both ongoing and completed) in the
treatment of cancer.
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